At Veridex CRS, we want to make your rare cell research as easy as possible, and have provided answers to frequently asked questions. If you need more information, please email or call us today.
Veridex has been involved with conducting global clinical trials since 1999.
Our clinical trial testing services has been in business since 2007.
In August of 2008, most of the Immunicon assets were acquired by Veridex.
Our assay development process is divided into four major areas: Feasibility, Verification, Technical Transfer and Validation. Learn more about each area of our Assay Development.
We currently do not offer multiplex testing as part of our CRS service offering. Please check back as we are offering new services.
Our Cheshire Technology is a novel characterization technique that has been developed for re-interrogating single circulating tumor cells for multiple biomarkers. Cheshire testing is available only as a service because it requires special skills and equipment not yet commercially available. Learn more about Cheshire services.
Yes, beginning in 2011, we will have the capabilities to offer gene expression and mutational analyses. For more information, please contact your local business manager for our latest service offering.
When Rare Cell FISH is performed by our CRS Services lab, we are able to relocate the original CTCs and examine the FISH signals specifically in the rare cells.
Veridex ships CellSave Preservative Tubes and shipping supplies to your sites or CRO. The sites ship samples on the same day via overnight carrier to our lab in the United States or our European Lab. Learn more about our Global Testing Services.
No, tubes are shipped at ambient temperature.
Yes, we are able to receive samples for processing within the 96 hour window.
Samples need to be shipped at ambient temperature. Learn more about shipping samples.
Yes, we use EDTA tubes and they must be processed within 24-36 hours from collection. For molecular analysis such as gene profiling, the testing is performed on a sample collected in EDTA. For FISH analysis this may be done off of a standard CellSave tube.
Our databases and reports are customized to meet the needs of the individual trials. Please contact your local business manager with specific requirements.
Veridex and MGH have entered into a collaboration to develop and commercialize a next-generation circulating tumor cell (CTC) technology for capturing, counting and characterizing tumor cells found in patients' blood. The collaboration will involve Ortho Biotech Oncology Research & Development (ORD), a unit of Johnson & Johnson Pharmaceutical Research & Development. It focuses on the development of a next-generation system that will enable CTCs to be used both by oncologists as a diagnostic tool for personalizing patient care, as well as by researchers to accelerate and improve the process of drug discovery and development.
The CellSearch® CXC Kit gives you flexibility to study low-density markers of interest on circulating epithelial cells. The CellSearch® CXC Kit reagents include a cytokeratin-fluorscein (FITC), CD45- allophycocyanin (APC), leaving the phycoerythrin (PE) channel of the CellTracks Analyzer II® open to incorporate a user-defined PE-conjugate to further characterize the circulating epithelial cells. Learn more about the CXC Kit.
Veridex offers two tumor phenotyping reagents, HER-2/neu and EGFr, that allow you to analyze the cell's proteome. Learn more about Veridex Clinical Research Solutions Tumor Phenotyping Reagents.
Please refer to the white paper on Guideline for the Use and Optimization of User Defined Markers for information on how to use the open channel for markers other than those currently available by Veridex. Click here to access the paper
The CellTracks® Circulating Melanoma Cell Kit immunomagnetically captures CD 146-positive cells from whole blood. CMCs are defined as being CD146+, DAPI+, Mel-PE+ and CD45/CD34-. CD 146 is used as the capture mechanism. Learn more about the Circulating Melanoma Cell Kit.
This site is published by Veridex, LLC, which is solely responsible for its contents. © Veridex, LLC 2011. This site is intended for use by residents of the United States of America.
This information is intended for biotech, pharmaceutical, and/or academic researchers. The products/services discussed are for research use only and not for use in diagnostic
procedures. Last updated on: 22 April 2013